Biogen Pharmachem Board Approves 1:6 Bonus Share Issue, Raises Capital Limit

Biogen Pharmachem Industries Limited's board approved a significant 1:6 bonus share issuance, proposing to issue over 15 crore equity shares. This move will also see the company's authorized share capital increased from ₹91.00 crore to ₹108.00 crore.

Key Board Decisions

The Board of Directors met on March 23, 2026, approving a substantial bonus share issuance at a 1:6 ratio, meaning shareholders will receive six new equity shares for every one they hold. To facilitate this, the authorized share capital will be raised from the current ₹91.00 crore to ₹108.00 crore, accommodating the issuance of 15,04,33,833 equity shares of ₹1 each. Additionally, the board has approved the appointment of M/s. Goenka Mehta & Associates as the new Statutory Auditors to fill a casual vacancy. All these proposals are pending necessary shareholder approval via a postal ballot.

Impact for Shareholders and Governance

The bonus share issue aims to reward existing shareholders by increasing their stake in the company at no extra cost. It can also signal management's confidence in future prospects and enhance share liquidity. The increased authorized capital provides greater financial flexibility for future growth strategies. The appointment of new auditors is a key governance measure, ensuring independent oversight of financial reporting.

Historical Context

This marks Biogen Pharmachem's first bonus share announcement since January 1, 2000, making it a noteworthy event for long-term investors. Previously, M/s. Rishi Sekhri and Associates were listed as statutory auditors in the company's 30th Annual Report (2024-25), indicating a change in audit firms. The company, established in 1995 and formerly known as Sun Techno Overseas Limited, primarily trades shares and securities. However, some reports suggest the company is exploring operational opportunities and may not be actively involved in core business activities, raising questions about its current operational status.

Immediate Effects

• Existing shareholders will receive six bonus shares for each share held, proportionally increasing their total share count.
• The company's paid-up share capital is projected to rise from ₹90.26 crore to ₹105.30 crore following the bonus issue.
• Authorized share capital will be boosted to ₹108.00 crore, enhancing future financial flexibility.
• M/s. Goenka Mehta & Associates will become the new Statutory Auditors, responsible for financial compliance oversight.

Key Approval and Operational Risks

• Shareholder Approval: The most critical step is securing shareholder approval through a postal ballot for the bonus issue, capital increase, and auditor appointment. Without these approvals, these corporate actions cannot proceed.
• Operational Clarity: The company's reported status of exploring new operational opportunities while potentially not being actively engaged in its core business presents an underlying risk concerning its future direction and long-term sustainability.

Industry Context

While peers like Aarti Industries and Dr. Reddy's Laboratories focus on expanding pharmaceutical and specialty chemical portfolios through innovation, Biogen Pharmachem's recent actions center on capital structure and rewarding shareholders. Industry leaders are driving growth in a rapidly expanding specialty chemicals sector and targeting a $130 billion pharmaceutical market by 2030. In contrast, Biogen Pharmachem's current strategy appears focused on its capital base and shareholding structure, particularly after a prolonged period without bonus issuances.

Financial Details

• The proposed bonus share issuance is expected to draw ₹15.04 crore from the Securities Premium account.
• As of March 31, 2025, the company had ₹17.00 crore available in its Securities Premium account.
• The post-bonus paid-up share capital is estimated to reach ₹105.30 crore.

Looking Ahead

• The announcement of a record date to determine eligibility for bonus shares.
• The results of the shareholder postal ballot vote on the proposed resolutions.
• Confirmation of the timeline for issuing and crediting bonus shares.
• Any future disclosures clarifying the company's operational strategy and business development plans.